LB Pharmaceuticals to Participate in Upcoming June Investor Events
Rhea-AI Summary
LB Pharmaceuticals (Nasdaq:LBRX) will participate in two June 2026 investor conferences. Executives present at the Jefferies Global Healthcare Conference on June 4, 2026 at 2:35 p.m. ET and at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 16, 2026.
Webcasts and replays will be accessible on the company’s Investors > Events webpage.
Positive
- None.
Negative
- None.
News Market Reaction – LBRX
In the May 29 session, LBRX gained 1.60%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Earnings and update | Positive | +3.8% | Q1 2026 financials, strong cash position, and late-stage pipeline progress. |
| Apr 22 | Clinical data update | Positive | -3.2% | Phase 2 NOVA-1 schizophrenia results published in JAMA Psychiatry. |
| Apr 09 | Investor conference | Neutral | -7.4% | Announcement of presentation at Needham Virtual Healthcare Conference. |
| Mar 27 | Clinical data analysis | Positive | -2.8% | New Phase 2 NOVA-1 cognition analyses presented at SIRS congress. |
| Mar 26 | Earnings and update | Positive | -2.8% | FY 2025 results and advancement of LB-102 into late-stage development. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows frequent negative price reactions to positive or neutral updates, with only one of the last five news events seeing a positive 24-hour move.
Over the past few months, LB Pharmaceuticals reported Q1 2026 results with cash of $365.6 million and multiple late-stage trials underway, including Phase 3 NOVA-2 and Phase 2 ILLUMINATE-1. Positive Phase 2 NOVA-1 data in schizophrenia were published in JAMA Psychiatry, and additional cognition analyses were presented at SIRS. The company has also regularly communicated through investor conferences. Today’s conference-related announcement continues this pattern of active investor outreach and late-stage program execution.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced that members of its executive team, will present and participate in the following upcoming investor conferences:
Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 2:35 p.m. ET
H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
Date: Tuesday, June 16, 2026
Time: Presentation available on the LB Pharmaceuticals website
The webcasts for the presentation and fireside chat will be available on the “Investors” page section under the “Events” section of the Company’s website at https://ir.lbpharma.us/, where a replay of the webcasts will be archived.
About LB Pharmaceuticals
LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a broad range of neuropsychiatric diseases.
Media and Investor Contact:
Ellen Rose
erose@lbpharma.us
